Enzo Biochem reports Q4 revenue improved sequentially by 20%

Enzo Life Sciences’ fourth quarter revenue improved sequentially by 20%, and year over year by 13%, driven by increased demand in multiple product areas and certain key customers. “The successful divestment of our Laboratory Services business has provided Enzo with the opportunity to open up an exciting new chapter in the ongoing story of our Life Sciences division,” said Kara Cannon, Enzo’s Interim CEO. “Our technical expertise and culture rooted in a deep understanding of customers’ needs has driven consistent revenue performance and margin improvement in Life Sciences. I couldn’t be more excited about the opportunities we see ahead to stabilize our infrastructure, return to consistent revenue growth, and improve margin performance through market expansion, channel focus, and cost containment. New product platforms, including our Life Science Validation service and our AMPIVIEW(TM) RNA probes, demonstrate our ability to provide technically relevant products to satisfy our drug development client demands, and we are committed to developing and delivering an innovative product portfolio that achieves greater results for our customers,” continued Cannon.